Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: RTOG 1115 Principal Investigator: Michalski, Jeff
Title: Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with A GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GNRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
Phase: III Disease Site: Prostate
Participating Site(s):
 
Main Campus
Map and Directions		 West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
The purpose of this study is to compare the effects of hormone therapy (androgen
deprivation) and TAK-700 plus radiation therapy with hormone therapy (androgen deprivation)and radiation therapy on you and your prostate cancer to find out which therapy is better. TAK-700 is an experimental drug, which means it is not approved by the FDA. TAK-700 is a pill intended to further reduce the levels of testosterone and other male hormones that may also cause continued growth of your prostate cancer. There are 2 treatment groups in this study: 1) Patients who receive hormone therapy plus radiation therapy only 2) Patients who receive hormone therapy and TAK-700 plus radiation therapy
 
More Information:
ClinicalTrials.gov Entry
Internal Protocol Documents (requires Siteman administrative database password)